%0 Letter
%T Addressing bottlenecks in Lassa fever treatment: overcoming the ribavirin parenteral formulation challenge.
%A Lawal QO
%A Okoeguale J
%A Oiwoh SO
%A Akhigbe T
%A Eifediyi RA
%A Okogbenin SA
%J Trop Med Health
%V 52
%N 1
%D 2024 Jul 8
%M 38978104
暂无%R 10.1186/s41182-024-00609-0
%X Ribavirin ampoule formulation remains a major challenge in managing Lassa fever disease. Lassa fever is an endemic viral hemorrhagic fever in the West Africa subregion, which has high-dose ribavirin as the standard of care. The high-dose therapy required makes the 200 mg/ml ampoule dosing of ribavirin a daunting task to administer, especially during disease outbreaks. This commentary highlights the challenges and makes a passionate call for vial dosage adjustment to fit the high-dose requirement of Lassa fever disease.